The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) was associated with a reduced risk for new ...
Liver failure, which can start suddenly or develop slowly, has a high mortality risk because of the swift onset of hepatocellular dysfunction. At least 30,000 patients in the USA and in Europe are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback